Tolimidone
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02317796)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase LynACTIVATOR
LYN activator
- Tyrosine-protein kinase LynPOSITIVE ALLOSTERIC MODULATOR
Tyrosine-protein kinase Lyn positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(Oc2cnc(=O)[nH]c2)c1- Mol. weight
- 202.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL8030 ↗
Also known as
- 5-(3-methylphenoxy)-2(1h)-pyrimidinone
- mlr-1023
- mlr-1023
- mlr-1023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06474598 | Phase 2 | Nov 30, 2024 | University of Alberta |
| NCT03279263 | Phase 2 | Sep 30, 2017 | Bukwang Pharmaceutical, Melior Pharmaceuticals |
| NCT02317796 | Phase 2 | Dec 1, 2014 | Bukwang Pharmaceutical, Melior Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bukwang Pharmaceutical | For profit | 2 | 0 | 1 | 2014 |
| Melior Pharmaceuticals | For profit | 2 | 2 | 1 | 2014 |
| University of Alberta | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1